Clinical Report: FDA clears pTau217 blood test for Alzheimer's disease

Overview

The FDA has cleared the Elecsys Phospho-Tau (217P) Plasma blood test to assist in identifying amyloid pathology in patients aged 55 and older with cognitive decline. This single-biomarker assay provides classifications to inform further diagnostic evaluation.

Background

Alzheimer's disease is a significant public health concern, with early and accurate diagnosis being crucial for patient management. The identification of amyloid pathology is a key component in the diagnostic process for Alzheimer's, and blood-based biomarkers offer a less invasive alternative to traditional imaging methods.

Data Highlights

The Elecsys pTau217 test classifies results as positive, intermediate, or negative for amyloid pathology. It was evaluated in patients aged 55 years and older with cognitive decline, showing high concordance with amyloid PET imaging.

Key Findings

• The Elecsys pTau217 test aids in both rule-in and rule-out assessments of amyloid pathology.
• It is intended for use alongside clinical information and other diagnostic findings.
• The test can be integrated into existing laboratory workflows without additional instrumentation.
• Results from the test are highly concordant with amyloid PET imaging.
• The assay has not been established for predicting future dementia or tracking therapeutic responses.

Clinical Implications

The Elecsys pTau217 test supports the diagnostic evaluation process but should be used in conjunction with other clinical assessments.

Conclusion

The clearance of the Elecsys pTau217 blood test by the FDA marks a significant step in the diagnostic evaluation of Alzheimer's disease.

Related Resources & Content

1. Roche, FDA Press Release, 2026 -- FDA clears pTau217 blood test for Alzheimer's disease
2. MDSpire News, 2026 -- P-Tau217/β-Amyloid Ratio Blood Test Gains Breakthrough Status
3. MDSpire News, 2026 -- First Alzheimer's Test for Primary Care
4. The Alzheimer's Association Clinical Practice Guideline, 2025 -- Blood-Based Biomarkers
5. the pathologist — Blood Test Forecasts Alzheimer's Onset
6. mdspire news — FDA approves tau PET imaging agent
7. Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer’s disease assessment across primary and specialty care
8. Alzheimer's Association Clinical Practice Guideline on the use of blood‐based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings - Palmqvist - 2025 - Alzheimer's & Dementia - Wiley Online Library
9. The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD‐ADRD): Executive summary of recommendations for specialty care - Dickerson - 2025 - Alzheimer's & Dementia - Wiley Online Library
10. Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis - ScienceDirect
11. Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease | Radiology | JAMA Neurology | JAMA Network
12. The Alzheimer's Disease Diagnosis and Plasma Phospho‐Tau217 (ADAPT) study stage 1: Validating clinical cut‐points against CSF and amyloid PET - Keshavan - 2026 - Alzheimer's & Dementia - Wiley Online Library